A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
National Cancer Institute (NCI)
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Conjupro Biotherapeutics, Inc.
Whitehawk Therapeutics, Inc.
City of Hope Medical Center
National Cancer Institute (NCI)
SystImmune Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Filamon LTD
On Target Laboratories, LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
ViroMissile, Inc.
Sichuan Enray Pharmaceutical Sciences Company
A2 Biotherapeutics Inc.
Tizona Therapeutics, Inc
Essen Biotech
National Institutes of Health Clinical Center (CC)
Clasp Therapeutics, Inc.
New Phase Ltd.
Revolution Medicines, Inc.
University of Colorado, Denver
Institut Bergonié
Royal Marsden NHS Foundation Trust
SystImmune Inc.
Pheon Therapeutics
Daiichi Sankyo
Grey Wolf Therapeutics
Second Life Therapeutics
Eli Lilly and Company
Seagen Inc.
Medical College of Wisconsin
Varian, a Siemens Healthineers Company
Novartis
Mayo Clinic
Seagen Inc.
RenJi Hospital
Degron Therapeutics Co.
University Health Network, Toronto